Pharmacologic properties of new anticoagulants.
| Medication . | Metabolism . | Half-life* . | Dosing** . | Monitoring . |
|---|---|---|---|---|
| *Half-lives reported are based on pharmacokinetic studies in adults. | ||||
| **Dosing for argatroban is based on a prospective clinical trial in children from birth to 16 years of age33 and additional information regarding dosing can be found in the prescribing information in the Physician’s Desk Reference, www.argatroban.com, or the FDA website. | ||||
| Dosing for bivalirudin is based on a prospective study in children less than 6 months of age.32 There are no data available for older children. | ||||
| Dosing for fondaparinux is based on the dose in the current prospective clinical trial. Thus far all 11 patients reached the target therapeutic level. | ||||
| †Fondaparinux levels are based on an anti-Xa level using a fondaparinux standard curve which is mathematically transformed to a concentration expressed in mg/L. | ||||
| Argatroban | 100% liver | 45 min | 0.75 μg/kg/min | 1.5–3 × baseline PTT |
| Bivalirudin | 75% proteolysis | 25 min | 0.125 mg/kg bolus | 1.5–2.5 × baseline PTT |
| 25% renal | 0.125 mg/kg/hr | |||
| Fondaparinux | 100% renal | 18 hrs | 0.1 mg/kg once daily | 0.5–1 mg/L 4 hours post-dose† |
| Medication . | Metabolism . | Half-life* . | Dosing** . | Monitoring . |
|---|---|---|---|---|
| *Half-lives reported are based on pharmacokinetic studies in adults. | ||||
| **Dosing for argatroban is based on a prospective clinical trial in children from birth to 16 years of age33 and additional information regarding dosing can be found in the prescribing information in the Physician’s Desk Reference, www.argatroban.com, or the FDA website. | ||||
| Dosing for bivalirudin is based on a prospective study in children less than 6 months of age.32 There are no data available for older children. | ||||
| Dosing for fondaparinux is based on the dose in the current prospective clinical trial. Thus far all 11 patients reached the target therapeutic level. | ||||
| †Fondaparinux levels are based on an anti-Xa level using a fondaparinux standard curve which is mathematically transformed to a concentration expressed in mg/L. | ||||
| Argatroban | 100% liver | 45 min | 0.75 μg/kg/min | 1.5–3 × baseline PTT |
| Bivalirudin | 75% proteolysis | 25 min | 0.125 mg/kg bolus | 1.5–2.5 × baseline PTT |
| 25% renal | 0.125 mg/kg/hr | |||
| Fondaparinux | 100% renal | 18 hrs | 0.1 mg/kg once daily | 0.5–1 mg/L 4 hours post-dose† |